Dermatology

The FDA accepted the dersimelagon NDA with priority review for EPP and XLP; a decision on the oral MC1R agonist is expected by February 2027.

Children with atopic dermatitis have higher ADHD risk, particularly with early, severe disease and sleep disturbance, a review found.

Baseline severity and clinical phenotype may help predict response to systemic therapy in children with alopecia areata.

Can you guess the diagnosis?

Can you guess the diagnosis?

Phase 3 data show lebrikizumab improved skin clearance, itch, and quality of life in children with moderate-to-severe atopic dermatitis.

A Rutgers-led study finds teens who follow beauty influencers or watch tutorials use significantly more personal care products, many containing endocrine-disrupting chemicals.

New approvals and emerging data are expanding nonsteroidal topical treatment options for several chronic pediatric skin conditions.

Adverse childhood experiences may affect pediatric skin disease risk and outcomes, but researchers say evidence remains limited.

A systematic review found chronic pediatric skin disorders are consistently associated with psychological distress, reduced quality of life, and caregiver burden.

A pooled ADORING trial analysis found tapinarof cream improved skin clearance by week 2 across ages 2 through adulthood in atopic dermatitis.

Tralokinumab showed expected pharmacokinetics and no new safety findings in 28 children with moderate-to-severe atopic dermatitis.

FDA expands approval of roflumilast cream 0.3% for plaque psoriasis to children aged 2 years and older, offering the first topical PDE4 inhibitor.

FDA approved risankizumab for children 6 and older with plaque psoriasis or psoriatic arthritis, adding a weight-based 55-mg syringe for those under 40 kg.

BM-3103 received FDA Fast Track designation for epidermolysis bullosa simplex as a phase 2 trial evaluates safety and efficacy.

New FDA-approved options for molluscum contagiosum—in-office cantharidin and at-home berdazimer gel—reduce stigma and avoid painful removal.

Learn how early detection and treatments for childhood eczema and hives can curb the atopic march and boost sleep, school, and quality of life.

The FDA has approved an every-8-week maintenance regimen for lebrikizumab-lbkz (EBGLYSS), giving eligible adults and adolescents with moderate-to-severe atopic dermatitis as few as 6 injections per year without mandatory topical therapy.

The FDA has approved bemotrizinol as the first new active sunscreen ingredient under the OTC monograph in nearly two decades, clearing the broad-spectrum UV filter for use in adults and children 6 months of age and older.

Colleen Cotton, MD, outlines a simple screening approach that may help pediatricians identify hidradenitis suppurativa earlier.

Colleen Cotton, MD, explains how early referral, flare management, and comorbidity screening may help improve outcomes for children with hidradenitis suppurativa.

Common pediatric skin infections are often managed in primary care, but some presentations require dermatology referral and further evaluation.

Early referral, school accommodations, and patient education may help improve quality of life for children with hidradenitis suppurativa.

Colleen Cotton, MD, FAAD, outlines key skin findings that may help pediatricians distinguish hidradenitis suppurativa from other conditions.

Early diagnosis of hidradenitis suppurativa in adolescents may help prevent scarring and improve treatment response, according to Colleen Cotton, MD, FAAD.